The hMSH2(M688R) lynch syndrome mutation may function as a dominant negative

Carcinogenesis

Volumn 33, Issue 9, 2012, Pages 1647-1654

  Martín López, Juana V ^a,b   Barrios, Ysamar ^a   Medina arana, Vicente ^c   Andújar, Miguel ^d   Lee, Sanghee ^e   Gu, Liya ^e   Li, Guo Min ^e   Rüschoff, Josef ^f   Salido, Eduardo ^a   Fishel, Richard ^b,g  

^a UNIVERSIDAD DE LA LAGUNA   (Spain)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^d HOSPITAL UNIVERSITARIO MATERNO INFANTIL DE CANARIAS   (Spain)

^e UNIVERSITY OF KENTUCKY   (United States)

^f Institute of Pathology Nordhessen   (Germany)

^g OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATE; HETERODIMER; PROTEIN MSH2; PROTEIN MSH6;

ADULT; ARTICLE; BINDING KINETICS; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CONTROLLED STUDY; DNA BINDING; DNA POLYMORPHISM; EXCISION REPAIR; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HETEROZYGOTE; HMSH2 GENE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; SURFACE PLASMON RESONANCE; WILD TYPE;

AMINO ACID SEQUENCE; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA MISMATCH REPAIR; DNA-BINDING PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MOLECULAR SEQUENCE DATA; MUTATION; MUTS HOMOLOG 2 PROTEIN;

EID: 84865544805     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs199     Document Type: Article

References (50)

1. Umar, A. et al. (2004) Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J. Natl Cancer. Inst., 96, 261-268.
2. Lipton, L.R. et al. (2004) Refining the Amsterdam Criteria and Bethesda Guidelines: testing algorithms for the prediction of mismatch repair mutation status in the familial cancer clinic. J. Clin. Oncol., 22, 4934-4943.
3. Fishel, R. et al. (1995) Identification of mismatch repair genes and their role in the development of cancer. Curr. Opin. Genet. Dev., 5, 382-395.
4. Kolodner, R.D. et al. (1999) Eukaryotic DNA mismatch repair. Curr. Opin. Genet. Dev., 9, 89-96.
5. Fishel, R. (1999) Signaling mismatch repair in cancer. Nat. Med., 5, 1239-1241.
6. Gong, J.G. et al. (1999) The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature, 399, 806-809.
7. Kat, A. et al. (1993) An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc. Natl Acad. Sci. USA, 90, 6424-6428.
8. Zhang, H. et al. (1999) Apoptosis induced by overexpression of hMSH2 or hMLH1. Cancer Res, 59, 3021-3027.
9. Fishel, R. et al. (1997) MutS homologs in mammalian cells. Curr. Opin. Genet. Dev., 7, 105-113.
10. Gradia, S. et al. (1999) hMSH2-hMSH6 forms a hydrolysis-independent sliding clamp on mismatched DNA. Mol. Cell., 3, 255-261.
11. Warren, J.J. et al. (2007) Structure of the human MutSalpha DNA lesion recognition complex. Mol. Cell., 26, 579-592.
12. Haber, L.T. et al. (1991) Altering the conserved nucleotide binding motif in the Salmonella typhimurium MutS mismatch repair protein affects both its ATPase and mismatch binding activities. Embo J., 10, 2707-2715.
13. Wu, T.H. et al. (1994) Dominant negative mutator mutations in the mutS gene of Escherichia coli. J. Bacteriol., 176, 5393-5400.
14. Alani, E. et al. (1997) Genetic and biochemical analysis of Msh2p-Msh6p: role of ATP hydrolysis and Msh2p-Msh6p subunit interactions in mismatch base pair recognition. Mol. Cell. Biol., 17, 2436-2447.
15. Antony, E. et al. (2006) Contribution of Msh2 and Msh6 subunits to the asymmetric ATPase and DNA mismatch binding activities of Saccharomyces cerevisiae Msh2-Msh6 mismatch repair protein. DNA Repair, 5, 153-162.
16. Drotschmann, K. et al. (2004) Mutations in the nucleotide-binding domain of MutS homologs uncouple cell death from cell survival. DNA Repair, 3, 729-742.
17. Iaccarino, I. et al. (1998) hMSH2 and hMSH6 play distinct roles in mismatch binding and contribute differently to the ATPase activity of hMut-Salpha. Embo J., 17, 2677-2686.
18. Medina-Arana, V. et al. (2006) New founding mutation in MSH2 associated with hereditary nonpolyposis colorectal cancer syndrome on the Island of Tenerife. Cancer Lett., 244, 268-273.
19. Yuan, Y. et al. (1998) Germline mutations of hMLH1 and hMSH2 genes in patients with suspected hereditary nonpolyposis colorectal cancer and sporadic early-onset colorectal cancer. Dis. Colon Rectum, 41, 434-440.
20. Banno, K. et al. (2003) Identification of germline MSH2 gene mutations in endometrial cancer not fulfilling the new clinical criteria for hereditary nonpolyposis colorectal cancer. Cancer Genet. Cytogenet., 146, 58-65.
21. Nomura, S. et al. (2000) Enhanced detection of deleterious and other germline mutations of hMSH2 and hMLH1 in Japanese hereditary nonpolyposis colorectal cancer kindreds. Biochem. Biophys. Res. Commun., 271, 120-129.
22. De Rosa, M. et al. (2000) Evidence for a recessive inheritance of Turcot's syndrome caused by compound heterozygous mutations within the PMS2 gene. Oncogene, 19, 1719-1723.
23. Gallinger, S. et al. (2004) Gastrointestinal cancers and neurofibromatosis type 1 features in children with a germline homozygous MLH1 mutation. Gastroenterology, 126, 576-585.
24. Hegde, M.R. et al. (2005) A homozygous mutation in MSH6 causes Turcot syndrome. Clin. Cancer Res., 11, 4689-4693.
25. Menko, F.H. et al. (2004) A homozygous MSH6 mutation in a child with cafe-au-lait spots, oligodendroglioma and rectal cancer. Fam. Cancer, 3, 123-127.
26. Poley, J.W. et al. (2007) Biallelic germline mutations of mismatch-repair genes: a possible cause for multiple pediatric malignancies. Cancer, 109, 2349-2356.
27. Gradia, S. et al. (1997) The human mismatch recognition complex hMSH2-hMSH6 functions as a novel molecular switch. Cell, 91, 995-1005.
28. Mazurek, A. et al. (2009) Sequence context effect for hMSH2-hMSH6 mismatch-dependent activation. Proc. Natl Acad. Sci. USA, 106, 4177-4182.
29. Gradia, S. et al. (2000) The role of mismatched nucleotides in activating the hMSH2-hMSH6 molecular switch. J. Biol. Chem., 275, 3922-3930.
30. Mazurek, A. et al. (2002) Activation of human MutS homologs by 8-oxo-guanine DNA damage. J. Biol. Chem., 277, 8260-8266.
31. Heinen, C.D. et al. (2002) HNPCC mutations in hMSH2 result in reduced hMSH2-hMSH6 molecular switch functions. Cancer Cell, 1, 469-478.
32. Shevchenko, A. et al. (1996) Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem., 68, 850-858.
33. Eisenthal, R. et al. (2007) Catalytic efficiency and kcat/KM: a useful comparator? Trends Biotechnol., 25, 247-249.
34. Guo, S. et al. (2004) Differential requirement for proliferating cell nuclear antigen in 5' and 3' nick-directed excision in human mismatch repair. J. Biol. Chem., 279, 16912-16917
35. Zhang, Y. et al. (2005) Reconstitution of 5'-directed human mismatch repair in a purified system. Cell, 122, 693-705.
36. Parsons, R. et al. (1993) Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell, 75, 1227-1236.
37. Medina-Arana, V. et al. (2004) Tumour spectrum of non-polyposis colorectal cancer (Lynch syndrome) on the island of Tenerife and influence of insularity on the clinical manifestations. Eur. J. Cancer Prev., 13, 27-32.
38. Medina Arana, V. et al. (2002) Highly aggressive leiomyosarcoma associated with Lynch II syndrome: increasing the range of extracolonic cancers related with hereditary non-polyposis colonic cancer. Ann. Oncol., 13, 807-808.
39. Gammie, A.E. et al. (2007) Functional characterization of pathogenic human MSH2 missense mutations in Saccharomyces cerevisiae. Genetics, 177, 707-721.
40. Wielders, E.A. et al. (2011) Characterization of MSH2 variants by endogenous gene modification in mouse embryonic stem cells. Hum. Mutat., 32, 389-396.
41. Ollila, S. et al. (2008) Mechanisms of pathogenicity in human MSH2 missense mutants. Hum. Mutat., 29, 1355-1363.
42. Jeong, C. et al. (2011) MutS switches between two fundamentally distinct clamps during mismatch repair. Nat. Struct. Mol. Biol., 18, 379-385.
43. Kolodner, R.D. et al. (2007) Coupling distant sites in DNA during DNA mismatch repair. Proc. Natl Acad. Sci. USA, 104, 12953-12954.
44. Gu, L. et al. (2002) Deficiency of a novel mismatch repair activity in a bladder tumor cell line. Nucleic Acids Res., 30, 2758-2763.
45. Valeri, N. et al. (2010) MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc. Natl Acad. Sci. USA, 107, 21098-21103.
46. Valeri, N. et al. (2010) Modulation of mismatch repair and genomic stability by miR-155. Proc. Natl Acad. Sci. USA, 107, 6982-6987.
47. Deschenes, S.M. et al. (2007) The E705K mutation in hPMS2 exerts recessive, not dominant, effects on mismatch repair. Cancer Lett., 249, 148-156.
48. Nicolaides, N.C. et al. (1998) A naturally occurring hPMS2 mutation can confer a dominant negative mutator phenotype. Mol. Cell. Biol., 18, 1635-1641.
49. Rahman, N. et al. (2007) Cancer genes associated with phenotypes in monoallelic and biallelic mutation carriers: new lessons from old players. Hum. Mol. Genet., 16 (Suppl. 1), R60-R66.
50. Parsons, R. et al. (1995) Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res., 55, 5548-5550.